| Name | CDK8-IN-13 |
| Description | CDK8-IN-13 is a CDK8 inhibitor (IC50: 51.9 nM) with potent, selective and oral activity. CDK8-IN-13 induces apoptosis and reduces the expression of p-STAT1 S727 and p-STAT5 S726. CDK8-IN-13 exhibits anti-tumour activity. |
| In vitro | CDK8-IN-13 (compound 43 ; 1, 2.5, 5, 10 µM ; 12 h) decreased p-STAT1 S727 and p-STAT5 S726 expression in HCT-116 cells in a dose-dependent manner.[1]
CDK8-IN-13 (0, 1, 5, 10 µM ; 48 h) induced apoptosis in a dose-dependent manner.[1] |
| In vivo | CDK8-IN-13 (40, 80 mg/kg ; orally ; for 15 days) inhibits tumor growth in a dose-dependent manner in mice.[1] |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 112.5 mg/mL (474.2 mM), Sonication is recommended.
|
| Keywords | CDK8-IN-13 | CDK8IN13 | CDK8 | Apoptosis |
| Inhibitors Related | Stavudine | 5-Fluorouracil | Flubendazole | Cysteamine hydrochloride | Myricetin | Sodium 4-phenylbutyrate | L-Ascorbic acid | L-Glutamic acid | Tributyrin | L-Ascorbic acid sodium salt | Alginic acid | Dextran sulfate sodium salt (MW 5000) |
| Related Compound Libraries | Apoptosis Compound Library | Bioactive Compound Library | Kinase Inhibitor Library | Hematonosis Compound Library | Inhibitor Library | Orally Active Compound Library | Anti-Aging Compound Library | Bioactive Compounds Library Max | Cell Cycle Compound Library | Anti-Cancer Compound Library | Anti-Cancer Active Compound Library |
United States
